Mastermind-like protein 2 (MAML2) is a critical transcriptional coactivator in the Notch signaling pathway. By forming a nuclear ternary complex with the Notch intracellular domain (NICD) and CSL (RBP-J), MAML2 drives the transcription of downstream oncogenic targets. Recurrent chromosomal translocations fusing MAML2 with CRTC1 or CRTC3 are established driver mutations in mucoepidermoid carcinoma (MEC) and other solid tumors. As therapeutic strategies shift toward disrupting these intracellular protein-protein interactions (PPIs) and fusion transcripts, high-quality discovery reagents are paramount to validating target engagement and cellular efficacy.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAML2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant Human MAML2 (Notch-binding Domain / Full Length) High purity (>95%), Endotoxin controlled, Sequence Verified. HEK293 or E. coli expressed for structural and binding assays. |
View MAML2 Products |
| Gene Delivery | MAML2 Promise-ORF / Lentivirus Particles Full-length ORF or CRTC1-MAML2 fusion constructs for stable cell line generation. |
View MAML2 Products |
| Benchmark Ab | Anti-MAML2 Recombinant Antibody High-affinity positive control for immunoprecipitation, Western blot, and ChIP assays. |
View MAML2 Products |
| Validator | MAML2 siRNA Set Target-specific knockdown pools for functional validation and specificity controls. |
View MAML2 Products |
| Related Target A | CRTC1 Partner in the oncogenic CRTC1-MAML2 fusion, a key therapeutic target in mucoepidermoid carcinoma. |
View CRTC1 Products |
| Related Target B | Notch1 Upstream receptor whose intracellular domain (NICD1) binds directly to MAML2 to initiate transcription. |
View Notch1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting the Dynamic Ternary Complex (NICD/CSL/MAML2) | Truncated MAML2 functional domains (Notch-binding region) with precise theoretical MW and high purity (>95%) to minimize non-specific aggregation in SPR/BLI assays. |
| Intracellular Delivery & Target Validation | High-titer Lentivirus particles expressing full-length MAML2 or CRTC1-MAML2 to construct robust reporter cell lines. |
| Lack of Reliable Screening Controls | Sequence-verified clinical benchmark antibodies and highly validated siRNA pools included to eliminate false-positive signals. |
Live MAML2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of MAML2 is rapidly evolving. Historically labeled as "undruggable" due to its nature as an intracellular transcriptional coactivator lacking a traditional enzymatic pocket, MAML2 is now at the forefront of precision oncology. The discovery landscape is transitioning from broad Notch pathway inhibition (such as γ-secretase inhibitors, which suffer from severe gastrointestinal toxicities) to highly specific inhibitors of the MAML2-containing transcription complex. Emerging modalities focus heavily on stapled peptides, small-molecule protein-protein interaction (PPI) disruptors, and targeted protein degradation (PROTACs) designed to selectively eliminate the CRTC1-MAML2 fusion protein while sparing physiological Notch signaling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic/Biotech Consortiums | Mucoepidermoid Carcinoma, Notch-driven Solid Tumors | Ternary complex assembly assays (Requires high-purity MAML2, NICD, and CSL recombinant proteins) |
| Stapled Peptides | Preclinical Stage Biotechs | T-cell Acute Lymphoblastic Leukemia (T-ALL), Triple-Negative Breast Cancer | Competitive binding assays (Requires sequence-verified MAML2 functional domains) |
| Targeted Degradation (PROTACs) | Oncology-focused Biotechs | CRTC1-MAML2 Fusion-positive Malignancies | Western blot and endogenous knockdown validation (Requires high-affinity Anti-MAML2 and validated siRNA sets) |